Skip to main content

Table 2 SCORAD index at the various times of stage 1 in groups A and B, and in stage 2 for groups A (placebo), B (treatment), placebo/placebo (AA) and treatment/treatment (BB) groups

From: Long-term treatment with low-dose medicine in chronic childhood eczema: a double-blind two-stage randomized control trial

 

N

Mean

SD±

% of change vs T0

p value

FIRST STAGE

 Group A placebo

  T0

40

13.93

8.28

  

  T3

37

11.00

11.08

21.0

0.2

  T6

34

10.15

11.71

27.1

0.12

  T8

33

8.15

4.15

41.5

0.001

  T14FU

32

6.53

3.21

53.2

0.0001

  total

177

10.18

8.83

  

 Group B treatment

  T0

40

14.71

7.65

  

  T3

35

9.74

10.25

33.8

0.0218

  T6

35

8.00

10.45

45.6

0.0026

  T8

33

6.79

4.08

53.8

0.001

  T14FU

33

5.30

3.82

63.9

0.0001

  total

177

9.17

8.47

  

SECOND STAGE

 Group AA placebo/ placebo

  T0

22

6.23

3.13

  

  T8

22

5.86

6.32

5.9

0.81

  T9FU

22

4.64

8.30

25.5

0.41

 Group BB treatment/treatment

  T0

27

5.22

3.75

  

  T8

27

5.07

3.05

2.9

0.87

  T9FU

27

3.52

2.59

32.6

0.058